Cerus sets November 2 results date for Cerus stock

Published on 10/20/2026 at 19:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 63.30 million for the period ended June 30, 2026. Cerus stock costs EUR 2.03 on October 20, 2026.

Reporting date and operating figures

Cerus Corporation announced a third-quarter results release for November 2, 2026.
Second-quarter revenue reached USD 63.30 million for the period ended June 30, 2026.
Cerus stock costs EUR 2.03 at Lang & Schwarz on October 20, 2026 at 7:03 p.m. CEST.

CERS, US1570851014, Illustration mit AI erstellt.

Cerus Corporation (US1570851014) announced that it will release third-quarter 2026 results on November 2, 2026, after the U.S. market close, according to ScanX. Cerus stock was trading at EUR 2.03 at Lang & Schwarz on October 20, 2026 at 7:03 p.m. CEST.

Revenue sets the starting point

Cerus reported USD 63.30 million in revenue for the second quarter ended June 30, 2026, compared with a USD 62.90 million consensus estimate, according to MarketBeat. The company recorded a USD 2.98 million net loss and an operating loss of USD 1.86 million in that quarter.

The upcoming release will test whether Cerus can sustain the revenue level while narrowing losses. MarketBeat reported a consensus revenue estimate of USD 63.25 million and a consensus loss of USD 0.0125 per share for the third quarter.

How does the stock compare?

On the Nasdaq, CERS was trading at USD 2.29 at 1:10 p.m. ET on October 20, 2026, with a market capitalization of USD 460.5 million and a negative price-to-earnings ratio of 62.98. The 52-week range was USD 1.38 to USD 3.47.

Comparison with peers: Cerus: 3.15 percent above the prior close, price-to-earnings ratio minus 62.98, market capitalization USD 460.5 million. Tandem Diabetes Care (Nasdaq, USD): 2.32 percent above the prior close, price-to-earnings ratio minus 18.04, market capitalization USD 1.2 billion. Envista Holdings (NYSE, USD): 0.46 percent above the prior close, price-to-earnings ratio 39.22, market capitalization USD 3.6 billion.

November 2 is the next date

The results release is scheduled for November 2, 2026, followed by a conference call at 4:30 p.m. ET, according to ScanX. The call is expected to address revenue, the loss profile and demand for the INTERCEPT Blood System.

Trading stays tied to results

The November report gives investors a concrete checkpoint for judging the gap between Cerus revenue and profitability. The company develops pathogen-reduction systems for platelets, plasma and other blood components.

The further course of trading is shown by the continuously updated real-time quote of Cerus stock.